10x Genomics, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Revenue $71.1m $146.3m $245.9m $298.8m $490.5m $516.4m $618.7m $610.8m $642.8m
Gross profit $60.5m $117.7m $184.9m $240.4m $416.4m $396.0m $409.3m $414.5m $443.9m
Research and development $32.2m $47.5m $83.1m $123.4m $211.8m $265.7m $270.3m $264.7m $238.6m
In-process research and development $62.4m $0 $447.5m $0 $0 $61.0m $0 $0
Selling, general and administrative $46.7m $87.9m $130.8m $202.3m $257.6m $298.3m $343.3m $344.3m $316.1m
Total operating expenses $78.9m $228.4m $215.4m $774.5m $468.7m $564.0m $674.6m $609.0m $504.9m
Gain on settlement $0 $0 ($49.9m)
Loss from operations ($18.4m) ($110.8m) ($30.6m) ($534.1m) ($52.3m) ($167.9m) ($265.3m) ($194.6m) ($61.0m)
Interest income $308k $1.0m $2.8m $1.5m $206k $6.6m $16.9m $18.4m $20.0m
Loss before provision for income taxes ($18.7m) ($112.4m) ($31.0m) ($534.5m) ($53.7m) ($162.0m) ($248.8m) ($177.7m) ($39.9m)
Provision for income taxes $21k $87k $218k $8.3m $4.5m $4.0m $6.3m $4.9m $3.6m
Net loss ($18.8m) ($112.5m) ($31.3m) ($542.7m) ($58.2m) ($166.0m) ($255.1m) ($182.6m) ($43.5m)
Total other income ($366k) ($1.6m) ($460k) ($334k) ($1.5m) $6.0m $16.6m $16.9m $21.1m
Net loss per share, basic (in dollars per share) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Net loss per share, diluted (in dollars per share) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Weighted-average shares used to compute net loss per share, basic (in shares) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Weighted-average shares used to compute net loss per share, diluted (in shares) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Cost of products and services revenue $10.6m $28.7m $61.0m $58.5m $74.1m $120.4m $209.4m $196.3m $198.9m
Interest expense ($811k) ($2.4m) ($3.1m) ($1.7m) ($866k) ($476k) ($33k) ($4k) $0
Other income (expense), net $137k ($249k) ($186k) $1.3m ($802k) ($198k) ($307k) ($1.6m) $1.0m